ISSN 1300-4948 | E-ISSN 2148-5607
Review
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report
1 Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey  
2 Division of Hematology, Department of Internal Diseases, Trakya University School of Medicine, Edirne, Turkey  
3 Division of Oncology, Department of Internal Diseases, İstanbul Medeniyet University School of Medicine, İstanbul, Turkey  
4 Department of Infectious Diseases and Clinical Microbiology & Institute of Medical Sciences, Sakarya University, Sakarya, Turkey  
5 Division of Gastroenterology, Department of Internal Diseases, İstanbul University İstanbul School of Medicine, İstanbul, Turkey  
6 Department of Gastroenterology, Sakarya University School of Medicine, Sakarya, Turkey  
7 Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University School of Medicine, Trabzon, Turkey  
8 Department of Gastroenterology, Ankara University İbn-i Sina Hospital, Ankara, Turkey  
9 Department of Infectious Diseases and Clinical Microbiology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey  
Turk J Gastroenterol 2018; 29: 259-269
DOI: 10.5152/tjg.2018.18263
Key Words: Hepatitis B, immunosuppressive therapy, reactivation risk, antiviral prophylaxis
Abstract

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions. 

 

 

 

Cite this article as: Aygen B, Demir AM, Gümüş M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018; 29: 259-69.

Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2018 Turkish Society of Gastroenterology | Latest Update: 29.06.2018